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PURPOSE. To determine in vitro release profiles, transcorneal permeation, and ocular injection
characteristics of a voriconazole-containing thermogel suitable for injection into the
subconjunctival space (SCS).
METHODS. In vitro release rate of voriconazole (0.3% and 1.5%) from poly (DL-lactide-co-
glycolide-b-ethylene glycol-b-DL-lactide-co-glycolide) (PLGA-PEG-PLGA) thermogel was deter-
mined for 28 days. A Franz cell diffusion chamber was used to evaluate equine transcorneal
and transscleral permeation of voriconazole (1.5% topical solution, 0.3% and 1.5%
voriconazole-thermogel) for 24 hours. Antifungal activity of voriconazole released from the
1.5% voriconazole-thermogel was determined via the agar disk diffusion method. Ex vivo
equine eyes were injected with liquid voriconazole-thermogel (48C). Distension of the SCS
was assessed ultrasonographically and macroscopically. SCS voriconazole-thermogel injec-
tions were performed in a horse 1 week and 2 hours before euthanasia and histopathologic
analysis of ocular tissues performed.
RESULTS. Voriconazole was released from the PLGA-PEG-PLGA thermogel for more than 21
days in all groups. Release followed first-order kinetics. Voriconazole diffused through the
cornea and sclera in all groups. Permeation was greater through the sclerae than corneas.
Voriconazole released from the 1.5% voriconazole-thermogel showed antifungal activity in
vitro. Voriconazole-thermogel was easily able to be injected into the dorsal SCS where it
formed a discrete gel deposit. Voriconazole-thermogel was easily injected in vivo and did not
induce any adverse reactions.
CONCLUSIONS. Voriconazole-containing thermogels have potential application in treatment of
keratomycosis. Further research is required to evaluate their performance in vivo.
Keywords: equine, voriconazole, subconjunctival, keratomycosis, thermogel, sustained-
release, PLGA-PEG-PLGA
Fungal keratitis, or keratomycosis, is a vision-threateningdisease well described in humans and animals world-
wide.1–3 In people, the reported incidence varies from 1.8%
to 70.0% of microbial keratitis cases, and is strongly influenced
by geographic and epidemiologic factors.4–9 Keratomycosis
occurrence is positively associated with warm, humid, sub-
tropical to tropical climates, and is negatively associated with
the degree of urbanization and gross domestic product of a
region.2,3 Keratomycosis is one of the most important causes of
ocular morbidity and vision loss in developing nations, where it
may account for more than half of corneal ulcers.4–7 It has also
recently been described as an emerging disease in more
temperate climates and affluent countries, such as France and
the United States, with case occurrence related to the presence
of traditional risk factors (e.g., agricultural work and ocular
trauma) and to the additional risk factor of soft contact lens
wear.3,10,11
Keratomycosis is an emerging disease associated with severe
morbidity in horses, with the reported incidence in North
America rising from 13% of keratitis cases in the 40 years
preceding 2006 to 25% in 2013.12–15 Horses serve as the only
naturally occurring, comparative animal model for human
keratomycosis, and are thought to be particularly prone to
fungal ocular infection due to their large globe size, unique
orbital shape and resultant globe exposure, suspected tear film
instability, and living environment.16,17 Clinical manifestations
of this disease in horses are very similar to those in people, and
include corneal ulceration, superficial punctate keratitis,
stromal abscessation, stromal plaque formation, and corneal
perforation.1,16,18,19 Fungal organisms and infiltrating immune
cells are capable of initiating both vigorous inflammatory
responses and protease overproduction in the cornea, which
may lead to the development of acute complications, including
rapid keratomalacia, unresolving ulceration, uncontrolled
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anterior uveitis, endophthalmitis, and corneal perfora-
tion.14,15,20 Long-term sequelae may include corneal scarring,
cataract or synechiae formation, phthisis bulbi, and vision
loss.1,14
Current treatment protocols for keratomycosis are expen-
sive, prolonged, and labor-intensive. Voriconazole, a second-
generation triazole antifungal drug, has recently become
widely used for treatment of both human and equine
keratomycosis due to its wide spectrum of antifungal activity,
low minimum inhibitory concentrations (MICs) against com-
mon pathogens, and excellent corneal penetration.13,21–23
A number of barriers to ocular drug penetration, such as
normal tear turnover, gravity-induced tear flow, blinking,
induced lacrimation, and corneal and conjunctival epithelial
tight junctions, limit the ability of topical medications to reach
the anterior ocular segment.24–28 Poor client/patient compli-
ance can further reduce the volume and frequency of drug
administration especially in horses due to their size, strong
eyelid musculature, and lack of tolerance for repeated
application of topical medications. Over the past decade, a
variety of biocompatible, biodegradable polymers have been
investigated for their potential as drug delivery carriers in an
attempt to overcome the aforementioned barriers.27,29,30
Thermosensitive biodegradable hydrogels (‘‘thermogels’’),
such as poly (DL-lactide-co-glycolide-b-ethylene glycol-b-DL-
lactide-co-glycolide) (PLGA-PEG-PLGA) are one such group of
polymers. They are administered as a liquid but form a gel
deposit upon reaching body temperature.29,31 Such polymers
are capable of maintaining a sustained release of drug at the
site of administration over weeks to months, thus increasing
the local bioavailability of the medication, decreasing systemic
side effects and improving client/patient compliance.28,29,32–35
The purpose of this study was to develop a thermogel
suitable for injection into the subconjunctival space (SCS) in
horses, as a natural animal model of human disease, that was
capable of sustained-release and delivery of voriconazole to the
cornea and anterior chamber.
MATERIALS AND METHODS
All protocols were approved by the Institutional Animal Care
and Use Committee of Auburn University and were conducted
in accordance with the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research.
Thermogel Preparation
Two commercially available, thermosensitive PLGA-PEG-PLGA
triblock copolymers (AK24 [molecular weight (Mw) ~1100–
1000–1100, 3:1 lactide:glycolide] and AK19 [Mw ~1500–
1500–1500, 1:1 lactide:glycolide]); Akina, Inc., West Lafayette,
IN, USA) were purchased in solid form (208C). Both PLGA-
PEG-PLGA thermogels were converted to an aqueous solution
via addition of 0.9% sodium chloride (80% wt/wt; Hospira, Inc.,
Lake Forest, IL, USA), vortexing for 1 minute every 8 hours for
48 hours and storage at 48C (liquid form). The two thermogel
solutions were combined in a 1:1 ratio to form a thermogel
with an optimal gelation setpoint of 32–368C36 (‘‘the thermo-
gel’’), concordant with that of the equine bulbar SCS (mean
temperature 6 SD: 34.58C 6 0.68C).37 Test groups containing
different concentrations of voriconazole were prepared as
outlined below. In all cases voriconazole crystals (US Pharma-
copeia, Rockville, MD, USA) alone or voriconazole crystals
dissolved in ethanol (Sigma-Aldrich Corp., St. Louis, MO, USA)
solution were added to the thermogel at 48C and the resultant
voriconazole-thermogel was vortexed for 1 minute every 8
hours for 48 hours to ensure even distribution of the drug
within the thermogel. The thermogel used for ex vivo injection
was stained with methylene blue (Akorn, Inc., Lake Forest, IL,
USA) for ease of visualization.
In Vitro Release Rate of Voriconazole From the
Thermogel
In vitro release rate determination was performed as described
previously.38,39 Six test groups were prepared, five consisting
of 300-lL aliquots of the thermogel combined with voricona-
zole in the following concentrations: 0% (group 1; negative
control group), 0.3% voriconazole (1 mg; group 2), 0.3%
voriconazole (1 mg as a 10% solution in ethanol; group 3), 1.5%
voriconazole (5 mg; group 4), and 1.5% voriconazole (5 mg as a
10% solution in ethanol; group 5), and one positive control
group consisting of voriconazole crystals alone (5 mg; group
6). The thermogels were prepared in glass vials at 48C (liquid
state). Conversion to a gel state was facilitated by suspension of
the glass vials in a water bath set at a constant temperature of
34.58C, where they were maintained for 28 days. Immediately
following gellation, 1 mL PBS (Lonza, Walkersville, MD, USA)
was added to each vial. The PBS was collected from the vials
and replaced with 1 mL fresh PBS at each sampling time point.
Samples were collected at 6, 12, 18, and 24 hours on day 1,
then every 24 hours for a further 27 days. Samples were stored
at 808C until analysis of voriconazole concentration via
reverse-phase HPLC. Observations of thermogel appearance
were recorded daily. Each formulation was tested in triplicate.
In Vitro Corneal and Scleral Voriconazole
Permeation
Five eyes were obtained from horses free from corneal and
scleral disease that were euthanized at the J. T. Vaughan Large
Animal Teaching Hospital (JTVLATH), Auburn University, AL,
USA, for reasons not related to this study. Enucleation was
performed immediately following euthanasia. Enucleated eyes
were placed in 0.9% saline (Baxter Healthcare Corporation,
Deerfield, IL, USA) and transported on ice to the laboratory
within 20 minutes of enucleation, where two paracentral
corneal and two dorsal scleral buttons were harvested from
each eye via the use of a corneal trephine (Asico, LLC,
Westmont, IL, USA) and Castroviejo corneal and Westcott
tenotomy scissors. In vitro permeation studies were performed
on vertical static Franz diffusion cells (PermeGear, Hellertown,
PA, USA). The harvested corneal and scleral buttons were
rinsed free of proteinaceous material with 0.9% saline and
placed horizontally between the donor and receptor halves of
individual cells (diffusion area 0.64 cm2), with the epithelial
surface of the corneal buttons and the external surface of the
scleral buttons facing the donor compartment. The receiver
chamber contained PBS (5 mL, pH 7.4), that was maintained at
348C to mimic the equine SCS temperature37 with a water
circulation jacket (378C) surrounding the lower part of the cell.
Stirring in the receptor chamber was maintained by a magnetic
bead. Three tests groups were determined on the basis of in
vitro release study results and the donor compartment loaded
with either 300 lL of a 1.5% voriconazole solution previously
shown to penetrate equine corneas in vivo13 (Vfend; Pfizer,
New York, NY, USA; group 1), 300 lL 0.3% voriconazole-
thermogel (group 2), or 300 lL 1.5% voriconazole-thermogel
(group 3). PBS samples were taken from the receptor chamber
and the receptor chamber was replenished with 1 mL fresh
PBS at 0, 2, 4, 6, 8, 12, and 24 hours. Samples were stored at
808C then analyzed for voriconazole content via reverse-
phase HPLC. Each group was tested in triplicate.
After 24 hours, each corneal button was rinsed thrice with
PBS to remove any remaining voriconazole or thermogel, dried
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and the ‘‘wet weight’’ (Wa) recorded. The corneal samples
were then desiccated at 708C for 8 hours and the ‘‘dry weight’’
(Wb) recorded. From these data, the percentage corneal
hydration was calculated (% corneal hydration ¼ [1  (Wa/
Wb)] 3 100), with a limit of 83% corneal hydration set for
inclusion of results in the study.40
High-Performance Liquid Chromatography
PBS samples were analyzed by reverse-phase HPLC as
previously described.41 The HPLC system (Agilent 1200
series) consisted of pumps, an autosampler, UV/visible light
absorption detector, column (4.6 mm  15 cm, 5 lm; Thermo
BetaBasic-18, Bellefonte, PA, USA), and computer interface.
The flow rate of the mobile phase was 1.0 mL per minute and
the mobile phase was 35% 0.1 M N, N, N¢, N¢-tetramethy-
lenediamine (Fisher Scientific, Inc., Waltham, MA, USA) and
methanol (Fisher Scientific, Inc.). An injection volume of 100
lL was selected. UV detection was at 254 nm with
voriconazole, and the internal standard, ketoconazole, show-
ing retention times of 3.7 and 13.5 minutes, respectively.
Calibration standards for voriconazole concentrations ranged
from 0.02 to 10 lg/mL and were prepared in dissolution
media and selected fluids. The lower limit of detection and
quantification for voriconazole was 0.02 lg/mL and 0.05 lg/
mL, respectively. Values of 1.96% and 5.01% were noted for
intra- and interday variations, respectively.
Antifungal Activity of Voriconazole Following
Release From the Thermogel
Antifungal activity of voriconazole released from group 4
thermogels was evaluated via the agar disk diffusion method,
as previously described.42–45 Briefly, Aspergillus flavus ATCC
204304 was grown on potato dextrose agar slants at 258C with
an aliquot subcultured onto Sabouraud dextrose agar (SDA) and
passaged to ensure purity and viability. After 4 days of incubation,
the slants were washed with sterile saline, Tween 20 (Sigma-
Aldrich Corp.) was added to improve conidia dispersion and the
suspension was adjusted to No. 1 MacFarland standard using
sterile saline as the diluent. For the inoculum, the cell density of
the suspension was adjusted until absorbance reading with a
spectrophotometer (Genesys 10S UV-VIS spectrophotometer;
Thermo Fisher Scientific, Waltham, MA, USA) was OD530 nm,
which equates to 0.4 3 106 CFU/mL to 5 3 106 CFU/mL.
Dilutions were then plated on SDA and incubated at 258C for 48
hours to confirm density. The inoculum was then swabbed onto
Mueller Hinton agar (MHA). Sterile paper disks were impregnat-
ed with 100 lL of the voriconazole-PBS solutions collected on
hours 6 and 12 and days 1, 5, 7, 14, 21, and 27 of the drug release
study and placed in triplicates on MHA plates, together with a
voriconazole control disk (1 lg, BD Sensi-Disk; Becton Dick-
enson and Co., Franklin Lakes, NJ, USA). Plates were incubated at
358C and examined at 24 and 48 hours, and the diameter of the
zone of inhibition was measured for each disk.
Characterization of Subconjunctival Injection of
the Thermogel in Ex Vivo Equine Eyes
Ten eyes were obtained from horses free from corneal and scleral
disease that were euthanized at the JTVLATH for reasons not
related to this study. Enucleation was performed immediately
following euthanasia via a transpalpebral approach and the
voriconazole-thermogel injected immediately following enucle-
ation. The temperature in the ventral SCS was measured
immediately before injection with a type T thermocouple
(Cole-Palmer, Vernon Hills, IL, USA) to ensure normothermia
was maintained. The thermogel (300 lL) in its liquid state (48C)
was injected under the dorsal bulbar conjunctiva through a 30-
gauge needle and the ease of injection and time taken to gel
formation recorded. Ultrasound biomicroscopy, 50 MHz (UBM)
(Aviso TM, 2016; Quantel Medical, Bozeman, MT, USA) was used
to visualize the thermogel deposit, describe its location and
shape, and measure its dimensions. The eyes were then frozen
with liquid nitrogen, sectioned using a microtome blade, and the
gross appearance of the gel deposit further described.
Short- and Mid-Term Toxicity Pilot Study in a
Single Live Horse
Following validation of this procedure ex vivo, the purpose of
this portion was to evaluate short-term (2 hours, left eye) and
mid-term (7 days, right eye) clinical tolerance of, and
histopathologic changes following, SCS injection of voricona-
zole-thermogel in a healthy adult horse.
The horse was sedated with 5 mg detomidine hydrochloride
(Dormosedan; Zoetis, Inc., Florham Park, NJ, USA) and 5 mg
butorphanol tartrate (Torbugesic; Zoetis, Inc.) IV, and local
ocular anesthesia was supplied through administration of
perineural 2% lidocaine hydrochloride (Hospira, Inc., Lake
Forest, IL, USA) around the auriculopalpebral and frontal nerves
and topical 0.5% proparacaine hydrochloride (Akorn, Inc.). The
eye was prepped with sterile diluted 5% betadine, irrigated with
sterile eyewash (Purdue Products, L.P., Stamford, CT, USA) and
300 lL 1.5% voriconazole-thermogel was injected into the right
dorsal SCS through a 30-gauge needle. Flunixin meglumine (1.1
mg/kg IV; Banamine: Intervet International, Intervent, Inc.,
Madison, NJ, USA) was administered immediately post injection
and topical ocular neomycin-polymixin-bacitracin ointment
(Vetropolycin; Dechra Veterinary Products, Overland Park, KS,
USA) was applied to the treated eye every 6 hours for 48 hours
following injection. A complete ophthalmic examination,
including Schirmer tear test (Schering-Plough, Charlotte, NC,
USA), biomicroscopy examination (SL-14; Kowa, Tokyo, Japan),
tonometry (Tonovet, iCare, Vantaa, Finland), fluorescein test
(Akorn, Inc.), and funduscopy, was performed 1 day before and
7 days after the SCS injection. After pupillary dilation with
tropicamide 1% (Akorn, Inc.), the ocular fundus was photo-
graphed (Optibrand Clearview; Optibrand Ltd., Fort Collins CO,
USA). The horse was examined twice daily and monitored
closely for signs of inflammation, reaction, or pain in the treated
eye. A modified Hackett-McDonald microscopic ocular inflam-
matory scoring system was used to evaluate the ocular anterior
segment and anterior vitreous.46 Scores of the conjunctiva
(congestion; swelling; discharge; 0–4); aqueous flare (0–3);
pupillary light reflex (0–2); iris involvement (0–4); cornea
(involvement and area; 0–4); pannus (vascularization; 0–2); and
anterior vitreal cellular infiltrate (0–4) were summed to provide
a single inflammatory score for each examination.46 Seven days
postinjection the horse was anesthetized with xylazine (1.1 mg/
kg IV; Anased; Akorn, Inc.), ketamine (2.2 mg/kg IV; Ketaset;
Fort Dodge Animal Health, Fort Dodge, IA, USA), and inhaled
isoflurane (Fluriso; Vet One, Boise, ID, USA), then euthanized for
reasons not related to this project with pentobarbital sodium
and phenytoin sodium (0.2 mL/kg; Beuthanasia-D; Intervet, Inc.,
Madison, NJ, USA). Following anesthetic induction (2 hours
before euthanasia) 300 lL of a 1.5% voriconazole-thermogel was
injected into the left dorsal SCS. Following euthanasia, both of
the horse’s eyes were enucleated and submitted for histopath-
ologic examination.
Data Analysis
Descriptive statistics (mean, median, range) were calculated
for measurements of thermogel deposit dimensions obtained
following ex vivo SCS injection and percentage corneal
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hydration following in vitro permeation studies (Microsoft
Excel 2013; Microsoft, Redmond, WA, USA). All data were
expressed as mean 6 SD. For the release study, rates of release
and transfer were obtained from slopes of cumulative amounts
released, unreleased, and transferred based on linear and log
coordinates. For first-order release, half-life (t1/2) was estimated
as 0.693 divided by the first-order rate constant. For the
permeation study, the cumulative amount of voriconazole
released from the thermogel as well the amount permeated
across cornea and sclera were plotted as a function of time.
The slope of the linear portion of the permeation data was
presented as flux or permeation rate (lg/cm2/h). Data were
analyzed by 1-way ANOVA followed by Dunnett’s test to
determine the level of significance between various groups.
The mean differences were considered significant at P < 0.05.
Data were analyzed using a commercial statistical analysis
program (GraphPad Prism software version 5; GraphPad, La
Jolla, CA, USA). For antifungal activity assessment, the
diameters of the growth inhibition zones around each disk
were measured in millimeters. A zone diameter equal to or
greater than 17 mm is the epidemiologic cutoff value for
detection of moulds with reduced susceptibility.45
RESULTS
Thermogel Preparation
Voriconazole appeared to combine with the thermogel in
groups 2, 3, and 5 to form an aqueous solution. Voriconazole
crystals appeared to disperse within the thermogel forming a
suspension in group 4. The thermogel retained its thermosen-
sitive properties following combination with voriconazole
alone, voriconazole in ethanol solution, and methylene blue.
In Vitro Release of Voriconazole From the
Thermogel
Voriconazole displayed sustained release from the thermogel
throughout the study period for all formulations, with peak
release occurring on day 1 for all voriconazole-thermogel
groups (groups 2–5; Figs. 1, 2). Voriconazole release from the
thermogel followed first-order kinetics with release t1/2 ranging
from 1.82 (group 3) to 4.22 days (group 2). The concentrations
released exceeded the target MIC (0.5 lg/mL) for 28 days in
groups 2 and 4 and 16 days in groups 3 and 5 (Fig. 2). There
was no voriconazole detected at any time in samples from the
negative control group (group 1), and voriconazole was
undetectable by day 6 in the positive control group (group
6). The addition of ethanol inconsistently altered the nature of
voriconazole release from the thermogel (Fig. 1).
Phase separation of the thermogel into liquid and gel
components occurred within the first 24 hours, and visual
degradation of the thermogel occurred from day 9, in all
groups. Greater thermogel breakdown occurred in the groups
without ethanol (1, 2, and 4), in which approximately 30% of
the original volume remained at day 28 compared with those
with ethanol (3 and 5), in which approximately 50% remained
(Fig. 3).
In Vitro Corneal and Scleral Voriconazole
Permeation
Permeation of voriconazole through the equine cornea and
sclera was observed for all formulations (Fig. 4). The sclera was
2-fold more permeable than the cornea to the 1.5% voricona-
zole solution (P < 0.001). Both corneal and scleral permeation
data demonstrated a concentration-dependent increase in the
permeation of voriconazole from the thermogel. The perme-
ation rate through the sclera or cornea for 1.5% voriconazole-
thermogel was at least 3-fold higher than that of 0.3%
voriconazole-thermogel (P < 0.001); 1.5% voriconazole-ther-
mogel showed significantly lower permeation as compared
with the 1.5% voriconazole solution through both the sclera
and cornea, suggesting the sustained release character of the
gel formulation. Corneal hydration was less than 83% in all
cases (81.5% 6 1.9%, 78.3%–82.9%).
Antifungal Activity of Voriconazole Following
Release From the Thermogel
The results of the antifungal activity testing of voriconazole
released from 1.5% voriconazole-thermogel (group 4) in
comparison with those of the reference compound, voricona-
zole (1 lg), are given in the Table. Voriconazole released from
1.5% voriconazole-thermogel showed moderate to good
inhibitory activity against Aspergillus flavus ATCC 204304
FIGURE 1. Percent cumulative voriconazole release from the thermogels. Voriconazole was sustainedly released from the thermogels throughout
the study period. Addition of ethanol inconsistently altered voriconazole release. TG, thermogel; V, voriconazole; ETOH, ethanol.
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(24–50 mm inhibition zone diameters) at every studied time
point.
Characterization of Subconjunctival Injection of
the Thermogel in Ex Vivo Equine Eyes
The thermogel was able to be easily injected into the dorsal
SCS through a 30-gauge needle. A discrete gel deposit was
formed in the SCS, which was able to be observed both grossly
and as a well-demarcated hypoechoic structure via UBM (Fig.
5). The deposits formed were small and ovoid with length 15.1
6 1.37 mm, width 10.1 6 1.65 mm, and maximum depth 1.3
6 0.25 mm (0.83–1.72 mm). Gelation occurred rapidly, with a
mean time from initiation of the injection to gelation of 16.4 6
1.65 seconds.
Short- and Mid-Term Toxicity Pilot Study in a
Single Live Horse
Dorsal SCS injection of the voriconazole-thermogel was easily
performed and well tolerated in vivo following administration
of IV sedation and local anesthesia (Fig. 6). The thermogel
remained in liquid form when stored in a syringe in a cooler
containing ice during the time it took to administer local
anesthesia and perform a sterile preparation of the eye, and
converted to a gel state within 10 seconds of completing the
injection. No local or systemic adverse reactions were noted in
the 7 days following injection, with the exception of self-
limiting chemosis and conjunctival hyperemia on days 2 and 3
postinjection. No significant difference was found from
baseline in the cumulative daily inflammatory scores through-
out the entire study period. The conjunctiva, sclera, cornea,
lens, retina, and optic nerve of both eyes were normal on
histologic examination, with no evidence of inflammation or
tissue damage observed after thermogel injection (Fig. 7).
DISCUSSION
This series of studies describes the development of a novel,
biodegradable, sustained-release ocular drug delivery system
for treatment of keratomycosis and its evaluation in vitro, ex
vivo, and in a pilot in vivo animal model. We demonstrated that
voriconazole when directly combined with a PLGA-PEG-PLGA
thermogel, is released in a sustained manner from the
thermogel in concentrations exceeding the MIC of common
ocular fungal pathogens for 28 days in vitro and is capable of
permeating the isolated equine cornea and sclera and effecting
sustained antifungal activity, following release. Furthermore,
we demonstrated that subconjunctival injection of the
thermogel is feasible in ex vivo and in vivo equine eyes under
sedation and local anesthesia and in a single horse was not
associated with adverse systemic, or local tissue, reaction.
FIGURE 2. Voriconazole concentration in PBS over time. Voriconazole release exceeded the target MIC (0.5 lg/mL) for 28 days in groups 2 and 4
and 16 days in groups 3 and 5.
FIGURE 3. Thermogel degradation over time. Addition of ethanol
slowed the degradation of the thermogel, with more thermogel
remaining in groups 3 and 5 than in groups 1, 2, and 4 at study
completion. (A) Group 1, day 1. (B) Group 3, day 1. (C) Group 1, day
28. (D) Group 3, day 28.
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PLGA-PEG-PLGA is a biocompatible, thermoactive polymer.
It was selected due to its proven safety, ease of injectable
administration through a minimally traumatic 30-gauge needle,
and sustained-release characteristics when combined with
small molecular weight, lipophilic drugs.30,47,48 As a biode-
gradable substance, PLGA-PEG-PLGA demonstrates advantages
over current alternate sustained-release devices available for
treatment of keratopathies, such as cyclosporine-containing
silicone-based matrix implants,38,49–51 as it is broken down by
endogenous enzymes and therefore does not require surgical
removal when it ceases releasing the loaded medication. The
mode of breakdown of bioactive polymers varies greatly; for
example, a PLGA and poly(d,l-lactide-co-caprolactone) micro-
film surgically implanted in the SCS of rabbits was found to
degrade via a combination of surface erosion and mass
degradation.52 The PLGA-PEG-PLGA thermogels used in this
study were noted to undergo phase separation within the first
24 hours. This physical characteristic may explain the high
voriconazole concentrations measured on days 1 to 2 of the
release study, with a large amount of voriconazole being
released from the hydrophilic thermogel fraction on day 1 and
the remainder undergoing very slow release together with
physical degradation of the hydrophobic thermogel matrix.33
This property may connote a clinical advantage, with high
concentrations of voriconazole achieved in the target tissues
during the first 48 hours following injection, at the time of first
exposure of the fungal pathogen to this medication.
Voriconazole is a triazole antifungal agent that is recom-
mended as a first-line agent for treatment of keratomyco-
sis.21,23,53,54 Despite effective corneal penetration, its topical
effect is short lived, with studies in rabbits demonstrating the
need for administration of voriconazole every 30 minutes to
FIGURE 4. Permeation of voriconazole across the (A) and (B) cornea and (C) and (D) sclera over time. A concentration-dependent increase in the
permeation of voriconazole from the thermogel formulations was noted, with the permeation rate through the sclera or cornea for group 3 at least
3-fold higher than that of group 2 (P < 0.001). Group 3 showed significantly lower permeation as compared with the 1.5% voriconazole solution,
suggesting the sustained release character of the thermogel.
TABLE. Antifungal Activity
Time
Inhibition Zone Diameter, mm
Control:
Voriconazole
Voriconazole-1.5%
Thermogel
6 h 30 47.3 6 2.3
12 h 28 43 6 3.5
1 d 30 40 6 0.0
5 d 34 50 6 0.0
7 d 36 50 6 0.0
14 d 32 38 6 2
21 d 36 30 6 4.6
27 d 35 24 6 5.2
Antifungal activity of voriconazole in PBS released at several time
points over a 28-day period from 1.5% thermogel (group 4) against
Aspergillus flavus ATCC 204304. The value obtained for each time
point represents the mean of three independent measurements 6 SD.
FIGURE 5. A 300-lL PLGA-PEG-PLGA thermogel deposit in the dorsal
SCS of an ex vivo equine eye as identified by (A) visual inspection, (B)
visual inspection following freezing with liquid nitrogen and section-
ing, (C) performing UBM after thermogel injection, and (D) sono-
graphic image obtained (50 MHz).
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achieve a sustained high concentration of voriconazole in the
anterior chamber.55 Previous research has been conducted into
lisosomal, nanoparticle-encapsulated, and microemulsion for-
mulations of voriconazole, and contact lenses impregnated
with alternative antifungal agents, to try to increase the contact
time with the cornea, and therefore provide more sustained
therapeutic drug levels following administration, whereas this
study aimed to develop a depot thermogel formulation to
prolong drug delivery to the anterior segment following
injection.56–59 In this study, voriconazole was shown to
permeate isolated equine corneas and sclerae in aqueous
solution, and following release from the thermogel, in vitro.
The 1.5% voriconazole-thermogel showed significantly lower
permeation as compared with the 1.5% voriconazole solution,
consistent with exposure of the tissues to a lower concentra-
tion of voriconazole in the thermogel groups. This finding was
expected, as the voriconazole in solution was immediately
available to the tissues for permeation; however, the voricona-
zole in the thermogel was sequestered from the tissues until it
underwent release from the thermogel matrix. An additional
factor that may have improved the permeation of the
voriconazole in solution was the presence of cyclodextrins,
an excipient used to increase solubility of voriconazole, in the
commercial voriconazole solution.60 Cyclodextrins have been
shown to increase the permeability of lipophilic drugs through
the cornea in other in vitro Franz diffusion cell studies.60
Transconjunctival permeation followed by corneal absorp-
tion, reflux out of the injection site, and direct penetration
through the sclera are all proposed mechanisms of transport of
medication to the anterior chamber following subconjunctival
injection.61,62 Scleral permeation was 2-fold higher than
corneal permeation for the 1.5% voriconazole solution in this
study, indicating that successful delivery of voriconazole
through the sclera following subconjunctival injection is
possible. This discrepancy is likely the result of structural
and physiological differences between the tissues tested. The
sclera has 10 times fewer glycosaminoglycans than the cornea,
and the scleral stroma has a greater degree of fibrillar
interweave than the corneal stroma.63 Diffusion across the
sclera as well as lateral diffusion within the sclera has been
studied extensively as a function of molecular weight and other
parameters, and greater permeation of drugs through the sclera
than the cornea is well reported.64 Similar permeation rates
were identified across both tissues in the 1.5% and 0.3%
voriconazole-thermogel formulations, further supporting the
validity of these thermogels as vehicles for sustained ophthal-
mic drug delivery, as permeation is concentration dependent
and this finding likely reflects lower exposure of the sclera to
voriconazole in the thermogel groups as it was slowly being
released from the thermogels than in the solution group. These
thermogels show significant potential for use in the treatment
of fungal ocular infections as the sustained achievement of
therapeutic concentrations of medication in the cornea and
anterior chamber is the goal of therapy and this can be
achieved in this case by a single injection of thermogel as
opposed to multiple topical applications of voriconazole
solution.
A number of limitations existed in this study. First, drug
release was measured only in vitro. Although the results were
promising, marked discrepancies in drug release kinetics and
longevity are often noted between in vitro experiments and in
vivo studies, when the hydrogel deposit is subjected to
biologic influences, such as constant blood flow and enzyme
degradation.65 Second, two samples were taken from each
equine cornea to create the corneal buttons used in the
permeation study. Corneal thickness varies by region in the
equine cornea; therefore, taking a single, central sample from
each cornea harvested would have increased uniformity of
tissues tested and reduced potential variability induced by
disparities in tissue thickness in the results.66 In this study, two
samples were taken from each cornea in an effort to reduce
mortality and each test group used corneal buttons from the
one horse in an effort to reduce the impact of additional
individual factors, such as breed and age, on corneal
thickness.67–69 Dissection of the corneas may have also
impacted the results as opposed to placing an entire cornea
with an intact scleral ring surrounding it into the Franz cell
chamber as occurs in human and small ruminant corneal drug
permeation studies. Corneal hydration was calculated to
evaluate damage to corneal tissue and to determine the validity
of samples for inclusion in the study. Corneal hydration was
less than 83% in all cases, the percentage correlated with
damage to the endothelium and or/epithelium of mammalian
corneas in in vitro permeability studies.40 Finally, the safety
assessment was a pilot study in one horse; therefore, further
assessment of potential toxicity of the voriconazole-thermogel
in a larger number of horses is essential before being used in a
clinical setting.
FIGURE 6. In vivo injection of 300 lL thermogel in the right eye of a
horse following administration of sedation and local anesthetic agents.
FIGURE 7. Histopathologic sections (hematoxylin and eosin) from the
right eye of a horse injected with 300 lL thermogel in the right dorsal
SCS 7 days before enucleation: (A) cornea (310); (B) ciliary body, iris,
limbus (32); (C) conjunctiva (310); (D) retina (340). No evidence of
inflammation or tissue damaged was observed on histopathologic
examination of either eye following injection of the thermogel.
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CONCLUSIONS
To the authors’ knowledge, this study constitutes the first
reported application of thermosensitive hydrogel technology
to develop an injectable agent for treatment of keratomycosis.
Results from this study are promising; however, further
research is required, and is currently under way, to assess the
safety, longevity, and performance of these thermogels in vivo.
If results of the in vivo experiments are positive, this thermogel
could reduce cost of treatment, improve compliance, and
increase treatment success rates for keratomycosis patients.
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